Changes Being Effected (CBE-30) MCQs With Answer

Introduction:
This quiz collection on “Changes Being Effected (CBE-30) MCQs With Answer” is designed specifically for M.Pharm students studying Documentation & Regulatory Writing. It focuses on the regulatory pathway that allows manufacturers to implement certain post-approval changes 30 days after the FDA receives the submission, unless the agency objects. The questions emphasize classification of changes (CBE-30 vs CBE-0 vs Prior Approval Supplement), required documentation, timelines, examples of appropriate changes, stability and validation expectations, and practical regulatory decision-making. These MCQs reinforce both theoretical concepts and applied regulatory judgment needed for managing post-approval modifications in pharmaceutical practice.

Q1. What does a CBE-30 submission allow a sponsor to do?

• Implement certain post-approval changes 30 days after FDA receipt unless FDA notifies otherwise
• Implement any post-approval change immediately upon submission without FDA notification
• Request FDA approval for major product changes before implementation
• Withdraw an application and resubmit with new data

Correct Answer: Implement certain post-approval changes 30 days after FDA receipt unless FDA notifies otherwise

Q2. Which regulatory citation is most directly associated with post-approval changes such as CBE-30 for NDAs and ANDAs?

• 21 CFR 314.70 (Changes to an approved application)
• 21 CFR 211 (Current Good Manufacturing Practice for finished pharmaceuticals)
• 21 CFR 820 (Quality System Regulation)
• 21 CFR 600 (Biologics General)

Correct Answer: 21 CFR 314.70 (Changes to an approved application)

Q3. How long must a sponsor typically wait after FDA receives a CBE-30 supplement before distributing the changed product if FDA does not object?

• 30 calendar days after FDA receipt
• Immediate distribution upon submission
• 90 calendar days after FDA receipt
• Until written approval from FDA is issued

Correct Answer: 30 calendar days after FDA receipt

Q4. Which statement correctly contrasts CBE-30 and Prior Approval Supplement (PAS)?

• CBE-30 is for changes with moderate potential impact and can be implemented after 30 days; PAS is for major changes requiring FDA approval before implementation
• CBE-30 requires prior written approval; PAS can be implemented after 30 days
• CBE-30 applies only to labeling; PAS applies only to manufacturing
• CBE-30 is used for biologics only while PAS is for small molecules

Correct Answer: CBE-30 is for changes with moderate potential impact and can be implemented after 30 days; PAS is for major changes requiring FDA approval before implementation

Q5. Which of the following is an appropriate example of a change that may be submitted as a CBE-30?

• A manufacturing process parameter adjustment within the validated range that has moderate potential impact on product quality
• Replacement of the active pharmaceutical ingredient with a different API
• Major formulation change that alters clinical performance
• Change in indication for use

Correct Answer: A manufacturing process parameter adjustment within the validated range that has moderate potential impact on product quality

Q6. Which change would most likely require a Prior Approval Supplement rather than CBE-30?

• Changing the drug substance (active ingredient) supplier with significant differences in synthetic route and impurity profile
• Minor editorial labeling clarifications that do not affect safety
• Tightening an acceptance criterion to be more stringent
• Adding a secondary packaging operation at a new site with no impact on product quality

Correct Answer: Changing the drug substance (active ingredient) supplier with significant differences in synthetic route and impurity profile

Q7. Which labeling change is typically suitable for submission as a CBE-30 rather than PAS?

• Addition of clarifying instructions for use that do not increase patient risk
• Changing the approved indication for the drug
• Removing essential contraindications or warnings
• Altering dosage strength without clinical bridging data

Correct Answer: Addition of clarifying instructions for use that do not increase patient risk

Q8. Which type of CBE allows implementation upon FDA receipt for immediate safety concerns?

• CBE-0 (Changes Being Effected – 0 days)
• CBE-30
• Prior Approval Supplement
• Annual Report

Correct Answer: CBE-0 (Changes Being Effected – 0 days)

Q9. What core elements must a CBE-30 supplement generally include?

• Detailed description of the change, scientific justification, supporting data or summary, and any proposed labeling changes
• Only a one-line notification without supporting data
• A full new clinical trial report for minor labeling edits
• Only a request for FDA opinion without implementing the change

Correct Answer: Detailed description of the change, scientific justification, supporting data or summary, and any proposed labeling changes

Q10. If the sponsor implements a CBE-30 change and the FDA notifies within 30 days that the supplement is not acceptable, what must the sponsor do?

• Cease distribution of the product incorporating the change and follow FDA’s direction
• Continue distribution and appeal later
• No action required; FDA cannot stop distribution after implementation
• Submit an Annual Report instead

Correct Answer: Cease distribution of the product incorporating the change and follow FDA’s direction

Q11. Is complete long-term stability data always required before implementing a manufacturing change under CBE-30?

• No; limited supporting stability data may allow implementation with a commitment to provide complete stability data post-approval
• Yes; complete long-term stability data is always mandatory prior to implementation
• Stability data is never required for CBE-30
• Only accelerated stability data submitted after 12 months is acceptable

Correct Answer: No; limited supporting stability data may allow implementation with a commitment to provide complete stability data post-approval

Q12. How does quality risk management contribute to deciding between CBE-30 and PAS routes?

• Risk assessment documents the potential impact on product quality/safety and supports justification for choosing CBE-30 or PAS
• Quality risk management is not relevant to regulatory classification decisions
• Risk assessments replace the need to submit any supplement
• Only clinical risk assessments are considered, not manufacturing quality

Correct Answer: Risk assessment documents the potential impact on product quality/safety and supports justification for choosing CBE-30 or PAS

Q13. For NDAs and ANDAs submitted electronically, in which format should a CBE-30 supplement be submitted?

• eCTD (electronic Common Technical Document) format
• Hand-delivered paper only
• Fax submission
• Email without structured modules

Correct Answer: eCTD (electronic Common Technical Document) format

Q14. True or False: CBE-30 is applicable only to small molecule drugs and not to biologics or BLAs.

• False — similar post-approval change pathways apply to biologics (with BLA-specific regulations) though the specific citations differ
• True — biologics cannot use any CBE mechanism
• True — biologics always require PAS
• False — CBE-30 is exactly the same for BLAs with no regulatory differences

Correct Answer: False — similar post-approval change pathways apply to biologics (with BLA-specific regulations) though the specific citations differ

Q15. What is a common regulatory expectation when a CBE-30 involves a process change that could alter impurity profiles?

• Provide comparative impurity and qualification data, risk assessment, and commit to any additional testing or stability studies
• No data is required if the change is documented
• Only a telephone call to the agency is adequate
• Immediately stop production until FDA issues a new approval letter

Correct Answer: Provide comparative impurity and qualification data, risk assessment, and commit to any additional testing or stability studies

Q16. Which of the following best describes the role of an approved comparability protocol in the context of post-approval changes?

• An approved comparability protocol can allow certain specified post-approval changes to be implemented without prior supplement or allow streamlined submissions as described in the protocol
• It eliminates the need for any regulatory submissions for future changes
• It is a voluntary internal SOP with no regulatory value
• It only applies to clinical protocol amendments

Correct Answer: An approved comparability protocol can allow certain specified post-approval changes to be implemented without prior supplement or allow streamlined submissions as described in the protocol

Q17. If a sponsor implements a change before FDA receives the CBE-30 supplement, is that consistent with regulatory expectations?

• No; for CBE-30 the supplement must be submitted and FDA must receive it; implementation should occur only after that receipt and the 30-day period unless another pathway applies
• Yes; implementation before submission is acceptable for CBE-30
• It depends on whether the change is labeling or manufacturing
• Only allowed if the sponsor notifies state authorities first

Correct Answer: No; for CBE-30 the supplement must be submitted and FDA must receive it; implementation should occur only after that receipt and the 30-day period unless another pathway applies

Q18. Which of the following changes would most likely be appropriate for a CBE-30 rather than an Annual Report?

• Changing a validated process parameter within a previously established and justified range that may moderately affect product quality
• Routine administrative changes with no effect on quality
• Major formulation changes that affect bioavailability
• Change in legal ownership of the marketing applicant

Correct Answer: Changing a validated process parameter within a previously established and justified range that may moderately affect product quality

Q19. Which documentation practice is recommended when submitting a CBE-30 to support regulatory review?

• Include summaries of validation, comparative characterization, analytical method changes, stability summaries, and a clear justification and risk assessment
• Only send raw lab notebooks without summaries
• Provide only marketing materials and no technical data
• Submit an audio recording explaining the change

Correct Answer: Include summaries of validation, comparative characterization, analytical method changes, stability summaries, and a clear justification and risk assessment

Q20. After implementing a change under CBE-30, what ongoing responsibilities does the sponsor retain?

• Maintain records, monitor product quality, submit any committed follow-up data, and respond promptly to FDA communications
• No further responsibilities once the product is distributed
• Only notify wholesalers of the change without documentation
• Transfer responsibility to the contract manufacturer exclusively

Correct Answer: Maintain records, monitor product quality, submit any committed follow-up data, and respond promptly to FDA communications

Download